Blood: Treating Refractable/Recurrent Non-Hodgkin's Lymphoma with CD19/CD20 CAR T Cells
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The chimeric antigen receptor T (CAR T) cells targeted at CD19 have made breakthroughs in the treatment of malignancies in the hematologic system (e.g., recurrent/refractive non-Hodgkinlymphoma, r/rNHL);In this study, researchers designed a number of series CARs (TanCAR) and found that these TanCAR T cells not only exhibited dual antigen targets of CD19 and CD20, but also showed superior and stableimmunesynaptic (IS) structure, which may be related to their strong anti-tumor activityin the open one-arm Phase I/IIa trial (NCT030977770), the researchers recruited 33 r/rNHL patients, 28 of whom infusion TanCAR T cells after conditional chemotherapyThe main purpose is to assess the safety and tolerance of TanCAR T cellsSecondary objectives are to assess efficacy, progression-free survival and overall survival14 (50%) patients with cytokine release syndrome (CRS), of which 36% had level 1 or 2 and 14% had stage 3No CAR T-cell-related encephalopathy syndrome (CRES) of level 3 or above occursOne patient died from treatment-related severe lunginfectionthe overall mitigation rate ofwas 79 per cent and the total mitigation rate was 71 per centThe progression-free survival rate at 12 months was 64 per cent In this study, TanCAR7 T cells were used in r/rNHL patients to cause an effective and long-lasting anti-tumor response without level 3 and above CRES
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
